Biodel names Gary Gemignani as CFO Biodel Inc (BIOD) announced that Gary Gemignani has been appointed as the company's CFO, effective September 15. Gemignani was most recently with Champions Oncology (CSBR) where he served as CFO and executive VP with responsibility for raising capital, investor relations and all financial operations.
Biodel initiates proof of concept study in Glucagon Emergency Management program Biodel has initiated enrollment of normal human subjects in a Phase 1 clinical trial of its lyophilized glucagon formulation designed for use in a proprietary auto-reconstitution device intended for the rescue of patients with severe hypoglycemia. The combination of the formulation and the auto-reconstitution device constitutes the Glucagon Emergency Management system, which is intended to be a more user-friendly glucagon presentation compared to emergency kits currently marketed. Biodel expects to report top line results of the Phase 1 proof of concept GEM study in late 1Q15.